Indokem (504092)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me start with a confession: I cannot value a business when the numbers do not line up. Indokem trades at ₹86.92, but the quoted 52-week range of ₹341.95–₹930.00 sits far above that. Either the series has been restated, there was a corporate action, or the data is wrong. Before I can trust anything else, that must be explained. At ₹242 Cr market cap, the company has a book value of ₹19.13 per share, so I am being asked to pay 4.54 times book for a business earning a 10.38% ROE and a 7.38% ROCE. Those are mediocre numbers, not franchise returns. Sales are down 3.18%, profits are down 44.59%, and the latest quarter shows ₹42 Cr of revenue with zero net profit. That is not earnings power; it is a hope. A trailing P/E of 284.32 tells me the market is valuing a small or vanishing profit at a huge price. The Piotroski F-score of 3/9 reinforces my concern about financial health. There is no dividend, so there is no return while I wait. Promoter holding is not disclosed, which bothers me in a small-cap Indian chemical company. Graham taught me to buy with a margin of safety, not to pay a premium for what used to be good news. Specialty chemicals can have moats, but I see no evidence of pricing power or durable demand here. The balance sheet data on debt is missing, so I cannot even assess solvency. This looks more like a speculative turnaround than a value investment. I will only watch it from the sidelines until I see stabilised sales, genuine profits, a real balance sheet, and a price that gives me book value at a discount.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer